BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 12975025)

  • 1. Gut peptides and type 2 diabetes mellitus treatment.
    Ahrén B
    Curr Diab Rep; 2003 Oct; 3(5):365-72. PubMed ID: 12975025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
    Meier JJ; Gallwitz B; Nauck MA
    BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut peptides in the treatment of diabetes mellitus.
    Vahl TP; D'Alessio DA
    Expert Opin Investig Drugs; 2004 Mar; 13(3):177-88. PubMed ID: 15013938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
    Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA
    Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin hormones--an update.
    Holst JJ; Orskov C
    Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucagon-like peptide-1 and control of insulin secretion.
    Thorens B
    Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
    Vahl T; D'Alessio D
    Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing incretin action for the treatment of type 2 diabetes.
    Drucker DJ
    Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
    Gallwitz B
    Diabetes Technol Ther; 2005 Aug; 7(4):651-7. PubMed ID: 16120042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
    Holz GG; Chepurny OG
    Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
    Nauck MA
    Acta Diabetol; 1998 Oct; 35(3):117-29. PubMed ID: 9840447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
    Baggio LL; Drucker DJ
    Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.